Literature DB >> 27734522

Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ).

Christina Kalpadakis1, Gerassimos A Pangalis2, Theodoros P Vassilakopoulos3, Maria Roumelioti4, Sotirios Sachanas2, Penelope Korkolopoulou5, Efstathios Koulieris2, Maria Moschogiannis2, Xanthi Yiakoumis2, Pantelis Tsirkinidis2, Charalampos Pontikoglou1, Dimitra Rondoyianni6, Helen A Papadaki1, Panayiotidis Panayiotidis4, Maria K Angelopoulou3.   

Abstract

Clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ) is a recently described entity characterized by the presence of clonal B cells in the blood and/or bone marrow (BM) with morphologic and immunophenotypic features consistent with marginal zone derivation in otherwise healthy individuals. CBL-MZ is commonly associated with paraproteinemia, usually immunoglobulin M (IgM), raising diagnostic difficulties from Waldenstrom macroglobulinemia (WM). The aim of the present study was to determine the presence of MYD-88 L265P mutation in a well-characterized series of CBL-MZ to identify cases that may in fact represent WM. Fifty-three CBL-MZ cases were retrospectively evaluated. MYD-88 L265P mutation was determined by allele-specific polymerase chain reaction in blood and/or BM mononuclear cells. Almost half of the CBL-MZ cases (49%) were associated with paraproteinemia mainly of the IgM type (65%). MYD-88 L265P mutation was identified in 10 cases (19%). These cases may truly represent WM, whereas 43 cases (81%) are still classified as CBL-MZ. Mutated cases were all associated with paraproteinemia compared with 37% of the nonmutated ones (P < .0001). In addition, mutated cases displayed more frequently CD38 and CD25 positivity (P = .002 and P = .005, respectively). Moreover, cases without paraproteinemia presented more frequently with lymphocytosis, irrespective of the presence of the MYD-88 mutation (P = .02). The present study demonstrates that MYD-88 L265P mutation may represent the only sensitive marker for the differentiation of CBL-MZ from probable WM. However, further studies are warranted to better define the biological significance of MYD-88 L265P mutation and to clarify whether the presence of the mutation establishes WM diagnosis or that it can also be present in borderline cases associated with paraproteinemia.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MYD-88 L265P mutation; clonal B-cell lymphocytosis

Mesh:

Substances:

Year:  2016        PMID: 27734522     DOI: 10.1002/hon.2361

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  3 in total

1.  CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up.

Authors:  Helen Parker; Neil Robert McIver-Brown; Zadie A Davis; Marina Parry; Matthew J J Rose-Zerilli; Aliki Xochelli; Jane Gibson; Renata Walewska; Jonathan C Strefford; David G Oscier
Journal:  Blood Adv       Date:  2018-05-22

2.  Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma.

Authors:  Maria Cristina Pirosa; Sven Borchmann; Fabrice Jardin; Gianluca Gaidano; Davide Rossi
Journal:  Hemasphere       Date:  2022-05-13

Review 3.  Liquid biopsy in lymphoma.

Authors:  Davide Rossi; Valeria Spina; Alessio Bruscaggin; Gianluca Gaidano
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.